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Abstract 
Objectives 
The advent of highly active anti-retroviral therapy (HAART) has turned Human 
Immunodeficiency Virus (HIV) infection into a chronic illness for those with access to 
medications. Despite having a predicted length of life comparable to age-matched healthy adults, 
many HIV-positive people are eager to be involved in curative trials. It is important for 
researchers to understand the motivations of these individuals when deciding to enroll 
participants into potentially dangerous studies. We present the results of a survey of HIV-
positive patients at two Boston hospitals to help inform future cure research. 
 
Methods 
Participants (n = 200) were age 23–74 (M = 51.9; SD 10.4), 76% of whom were mean. All had 
been HIV-infected for at least 6 months, on anti-HIV therapy with stable CD4 counts, and able to 
read English or Spanish. The survey was distributed to a convenient sample of HIV-positive 
people after routine physician visits at Massachusetts General Hospital and Brigham and 
Women’s Hospitals from June 2015 to February 2016. Participants were approached sequentially 
until the desired number of completed surveys was obtained. The survey consisted of 42 
questions, ranging from basic demographic information to hypothetical cure scenarios. Key 
topics addressed included a self-assesment of health status, stigmatization, household finances, 
willingness to take risk, and meaning of a cure. 
 
	ii	
Results 
The median time since diagnosis was 19 years [interquartile range (IQR) = 13, 24 years], with 
the median time on HAART of 15 years [IQR = 9, 20 years]. Seventy-three percent (142 of 195) 
stated that they would likely take a 1 in 100 chance of death in a trial, while 26% (51 of 196) 
stated they would likely take a 99 in 100 chance of death. Sixty-five percent (118 of 182) 
expected their health to be better in five years if they were cured of HIV compared to continuing 
their medications. Forty-one percent (75 of 182) estimated a 50% or greater risk that the virus 
would stop responding to their medications. Fifty-four percent (98 of 182) of respondents 
estimated a 50% or greater risk of experiencing serious side effects in the next 20 years due to 
their medications. Seventy-nine percent (154 of 196) of respondents reported some degree of 
stigma. 
 
Conclusions 
A substantial portion of the HIV-positive people we surveyed were willing to take a significant 
risk of death in pursuit of a cure. A majority felt that a cure would improve upon their current 
health state in the short-term, and reduce their risk of negative health outcomes over the next two 
decades. Uncertainty existed among our study participants as to how long their current treatment 
regimens will remain tolerable and effective. Most participants reported experiencing 
stigmatization, and factors such as psychological distress, burden of medications, and altruism 
also motivated enrollment in trials. Such motivations have implications for enrollment in 
curative trials.
 
 
 
 
		 1	
Why Risk Death for a Cure? 
A Survey of HIV Patients 
 
Introduction 
 With the development of highly active anti-retroviral therapy (HAART) in the mid-
1990s, Human Immunodeficiency Virus (HIV) infection has become a chronic disease for those 
with access to treatment. It is now widely assumed in the medical and research communities that 
individuals with HIV, on proper therapy, will have near normal quality of life and life 
expectancies.1 Despite this fact, there remains significant demand among HIV-positive people on 
stable therapy for a cure. A global survey of individuals with HIV found that 95% were 
interested in cure studies, with 59% willing to take “substantial risks”.2 Similar enthusiasm has 
been seen in America, and a recent survey found a majority of respondents desired to participate 
in a wide range of cure studies.3 
 At present, phase II/III HIV cure research studies are uncommon, but there are reasons to 
believe that many more are on the horizon. It is probable that many of these trials will entail a 
great deal of risk on behalf of the study participants, whether due to ingestion of a toxic 
medication or merely discontinuation of anti-retroviral therapy.4 This risk raises ethical concerns 
regarding enrollment of HIV patients, given that the expectation from the medical community is 
that they would attain marginal benefit to their health and quality of life. A great question of 
interest is what do people on stable HAART hope to gain from enrolling in potentially dangerous 
curative trials? 
 To date, there has been limited research into HIV patients’ motivations for participating 
in therapeutic studies.2, 5-15 Our group provided patients on stable HAART in Boston, MA with a 
survey to assess several potential motivators, including their current health status, expectations 
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for how their lives would change were they to be cured of HIV, and their willingness to enroll in 
clinical trials. This survey is meant as a pilot study to inform the hypotheses of future research. 
 
Methods 
 This study consisted of a cross-sectional survey of 200 people on stable anti-retroviral 
therapy at two hospitals in Boston, MA: Massachusetts General and Brigham and Women's. 
Participants were age 18 or older, HIV-infected for at least 6 months, on anti-HIV therapy with 
stable CD4 counts, and able to read English or Spanish. Clinical staff approached consecutive 
eligible patients from June 2015 to February 2016. Those who completed the survey were given 
a $10 gift card for their time. 
 The survey was distributed on paper and consisted of 42 questions, ranging from basic 
demographic information to hypothetical cure scenarios. Key topics addressed included a self-
assesment of health status, stigmatization, household finances, willingness to take risk, and the 
meaning of a cure. Question designs were mixed methods, including a 0-100 scale, a 5-point 
Likert scale, and several free-response questions. 
 The current utility scores for participants were measured using two metrics. The first was 
a 0 to 100 scale that asked for respondents to mark their current health status. The second, known 
as the EuroQol five dimension questionnaire (EQ-5D), is a standardized instrument for 
measuring generic health status. The five questions concern mobility, self-care, performing usual 
activities, pain/discomfort, and anxiety/depression. For each question, one of five responses can 
be given: “no problem,” “slight problem,” “moderate problem,” “severe problem,” and 
“unable”.14 Scores on each of these areas are combined into a single index score ranging from 0 
to 1.15 
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 To assess participants’ desire to enroll in risky clinical trials, each was presented with the 
question: “If there was a 1 in 100 chance you would die by taking this HIV treatment, and a 99 in 
100 chance you would survive and be cured of HIV, would you take this treatment?” The next 
question flipped these numbers: “If there was a 99 in 100 chance you would die by taking this 
HIV treatment, and a 1 in 100 chance you would survive and be cured of HIV, would you take 
this treatment?” The final question on risk taking asked: “If asked to take a treatment that 
included a chance of causing death, what is the largest chance of death (0-100) you would accept 
in order to be cured of HIV?” An individuals’ stated “largest chance of death” score was 
compared to the previous two questions to gauge the internal validity of responses. Statistical 
analyses were conducted on the quantitative data to assess for correlations between various self-
reported factors and participants’ willingness to take risk in clinical trials. 
 At the end of the survey, participants were presented with two free response questions: 
“What would an HIV cure mean to you?” and “How would your life be different (and what 
would be the same) now and in the future if you were cured of HIV?”. Two members of the 
research team read each free response answer and categorized responses based upon general 
theme. These designations aligned 91% of the time, and a third person resolved the few 
differences that arose. 
 
Results 
Respondent Characteristics 
 In total, 200 men and women completed the survey, either indepently or with assistance 
from a nurse. Overall, the mean age was 51.9 years (SD = 10.4) and approximately two-thirds of 
the participants were male [Table 1]. This findings is consistent with HIV-positive population as 
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a whole in the US, where 76% are men.16 The median length of time since HIV diagnosis was 19 
years (IQR = 13, 24), and the median length of time on anti-retroviral medications was 15 years 
(IQR = 9, 20). More than half (57.8%) of participants had at least some college education. The 
two utility scores were quite similar, with current health averaging 77.6 (SD = 16.7) and EQ-5D 
averaging 0.79 (SD = 0.2). 
 
Willingness to take risk 
 Participants reported a high willingness to risk death in order to enroll in potentially 
curative trials. For the question, “would you take a 1 in 100 risk of death”, 73% (142 of 195) of 
respondents answered that they “definitely” or “probably” would enroll in this trial, while only 
16% (32 of 195) stated they “probably” or “definitely” would not. To the question, “would you 
take a 99 in 100 risk of death”, only 26% (51 of 196) of respondents said they definitely or 
probably would, while 63% (123 of 196) answered they probably or definitely would not. 
 Of the 200 people to finish the survey, 179 (90%) answered the question on “largest 
chance of death (0-100) you would accept in a cure trial.” There was a wide distribution of 
responses, with a high percentage reporting significant willingness to take risk [Figure 1]. 
 While 18% (32 of 179) said that they would not take any risk of death in pursuit of a 
cure, more than a quarter (26%) said they would accept a greater than 50% chance of death. 
Thirteen individuals stated that they would take a 100% chance of death in pursuit of a cure, and 
25 people stated that they would take a 50% chance of death. 
 There were inconsistencies in some participant’s endorsement of willingness to risk death 
in a trial. A total of 50 respondents (26%) gave conflicting answers within this series of 
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questions. For example, 3 of the 13 people to report a “largest change of death” score of 100 also 
stated they “definitely” would not take a 99 out to 100 risk in the prior question. 
  
Expectation of health improvement 
 Most people believe a cure will improve their health status [Figure 2], which may 
contribute to their motivation to participate in a curative trial. The average current health score 
for our population was 77.6 (SD = 16.7), and this remained essentially unchanged when 
respondents predicted their health status five years from now if they continued their medications 
(M = 77.7, SD = 17.3). When asked to estimate their health status five years from now if they 
were cured, the score average rose to 89.1 (SD = 12.0). 
 Ten percent (20 of 198) of respondents said their health was “100” currently, and 32% 
(59 of 185) said it would be “100” in five years if cured. Sixty-five percent (118 of 182) of 
respondents expected their health to be better in five years if they were cured of HIV compared 
to continuing their medications. Among this group, 83% (98 of 118) thought their health would 
be better in five years than it is currently. While 32% (58 of 182) did expect their health to be the 
same in five years whether or not they were cured of HIV, only 8% (15 of 184) expected their 
health to be worse in five years if they were to be cured today.  
 This expectation of improved health status is partially explained by participant 
predictions that the likelihood of future negative health events would be reduced [Table 2]. More 
than half of respondents estimated that a cure would reduce their chance of having a heart attack 
or being diagnosed with cancer in the next 20 years (55% and 57%, respectively). A third among 
this group predicted this decline in risk to be “substantial.” Similarly, 59% thought their chance 
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of death over the next 20 years would be reduced. A much lower percentage of participants 
(20%) expected their chance of injury to change if they were cured of HIV. 
 
Concerns over medications 
 Many of the people we surveyed perceive a significant 20-year risk of their medications 
failing or causing serious side effects [Figure 3]. The median estimated probability that the virus 
would stop responding to medications was 30% (IQR = 10, 50), while the median estimated 
probability that participants would experience serious side effects from medications was 50% 
(IQR = 15, 70). 
 Forty-one percent (75 of 182) of respondents estimated a 50% or greater risk that the 
virus would stop responding to their medications. Twenty-three percent (41 of 182) gave a less 
than 10% chance of the virus would no longer respond to their medications in five years. Fifty-
four percent (98 of 182) of respondents estimated a 50% or greater risk of experiencing serious 
side effects in the next 20 years due to their medications. Fifteen percent (27 of 182) gave a less 
than 10% chance of experiencing serious side effects. 
 The answers to these two questions had a correlation coefficient of 0.6, indicating that 
many of the same people had concerns about their medications over the long-term. 
 
Stigma 
 There are factors outside the realm of current and future health status that may motivate 
someone to enroll in a clinical trial. Our population reported high levels of stigma, with nearly 
80% (154 of 196) of respondents reported some degree of stigma, and a third feeling “very” or 
“extremely” stigmatized [Figure 4]. 
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Written comments 
 Of the 200 people who completed the survey, 161 responded to one or both of the free 
response questions regarding the meaning of a cure. Several prominent themes emerged from 
those answers [Table 3].  
 The most commonly cited, burden of medications (36%), refers to both the concern that 
the medications are having harmful effects on the body (e.g. loss of bone density) as well as the 
need to take one or more pills every day.  
 Twenty-seven percent wrote that a cure would have a positive effect on their 
relationships. This broad category encompasses both feelings of stigmatization from society and 
challenges of intimacy related to HIV. These issues are closely related, as many people feel their 
romantic and social lives are limited due to the stigma that accompanies being HIV-positive. 
Also included in this category were worries of sexual transmission and the ways in which 
infection necessitates changes in behavior.  
 Nearly one-quarter of respondents emphasized that a cure would directly improve their 
health status in the long-term. Again, this finding is consistent with the earlier data regarding 
expected health improvement with a cure. 
 Less commonly cited but notable topics regarding the benefit of a cure included the 
ability to plan for the future (7%) and saving money on anti-retroviral medications (4%). A small 
number of people wrote about their distrust of researchers and clinical trials (2%), drawing from 
personal experience or the stories of others. Altruistic motivations for involvement in trials were 
cited for just over two percent of respondents. 
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Discussion 
 Previous studies have shown that there is substantial stated enthusiasm for involvement in 
risky curative trials by HIV-positive people.2,3 Our survey was designed to gain further insight 
into the reasons why people on stable antiretroviral therapy would choose to participant in such 
research.  
 A clear finding from our study was that a substantial portion of respondents say they are 
willing to take a significant risk of death in pursuit of an HIV cure. The reason for this desire to 
participate in risky trials appears to be tied to perceptions that a cure would improve an 
individual’s current health state. A majority of participants in our study believe their present 
health problems could be at least modestly reversed with a cure. This finding suggests that 
people with HIV attribute much of their current and future health status to the infection and/or 
their anti-retroviral medications. This belief seems to come, in part, from the idea that the 20-
year risk of heart attack and cancer would be reduced substantially by being cured of HIV. An 
important question for researchers becomes how realistic are these expectations, and do they 
align with our current understanding of HIV’s health effects? If the medical field believes that a 
cure is unlikely to improve upon an individual’s current health state, then it would be important 
to convey this to HIV-positive individuals before enrolling them in curative trials. 
 Another finding of the survey was that significant uncertainty exists among our study 
participants as to how long their current treatment regimens will remain tolerable and effective. 
Often it was the same people who were concerned about serious side effects as well as the virus 
no longer responding to their medications over the long run. These worries may cause 
psychological distress and could motivate someone to enroll in a risky clinical trial out of fear 
that their HAART will only benefit them for a limited period of time. Again, it will be important 
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for physicians and researchers to assess the validity of these concerns and to address them prior 
to enrolling people in trials. 
 Not all of the survey data focused on health related motivations for enrollment, and the 
vast majority of respondents stated that they experience at least some degree of stigmatization. 
While it has been speculated that overt stigmatization would be reduced now that HIV is treated 
like a chronic disease,17 it evidently remains prevalent in the lives of those that we surveyed.  
 The free-response section proved to be important for illuminating motivations for clinical 
trial enrollment that the pre-defined survey questions either did not address directly or with 
adequate depth. One of the primary takeaways from these comments was that many factors aside 
from current and future health status may motivate someone to enroll in a clinical trial. 
Consistent with the 5-point scale responses, social stigma was frequently reported in the free 
response section as well, and many participants wrote that it negatively influenced their 
relationships with family members and sexual partners. One of the most frequently cited changes 
a cure would provide was relief from the physical and psychological burden of taking anti-
retroviral medications. This is a consideration that may be underappreciated by clinicians and 
researchers. 
 As part of our statistical analyses, we used the “largest chance of death” score as an 
outcome variable to which we compared several other variables from the survey. Multivariable 
regression failed to show any consistently correlated independent variables. This remained true 
even when removing the respondents that were not internally consistent. The primary takeaway 
is that while there was a high stated willingness to accept risk in pursuit of a cure, we cannot take 
the absolute numbers collected here to be precise estimates of this risk. 
		 10	
 The use of the 0 to 100 “largest chance of death” scale proved to be one of the main 
limitations of our study. Two answers in particular arose repeatedly that made interpretation of 
the results challenging. The first was that 25 people stated that they would take a 50% chance of 
death. Evidence from other studies has shown that “50” is equivalent to “I do not know,” and is a 
fundamentally different response from either 45 or 55.18 The second issue that arose was that 13 
individuals stated they would take a 100% chance of death in pursuit of a cure. This could mean 
either that these people are willing to sacrifice themselves for the sake of finding a cure, are 
suicidal, or they did not understand the meaning of their answer. We cannot rightly know which 
it is, but when we compared these answers to the other risk questions (e.g. “99 in 100”) we found 
23% (3 of 13) gave conflicting responses. This points to the maximum risk score as being a 
difficult concept for many people, and therefore an imperfect measure of willingness to take risk. 
 The difficulty participants in our study had with the “willingness to take risk” measure 
raises concern for consent processes that utilize numbers or probabilities of events occurring.  
Alternative means of informing participants of associated risks may be to give more specific 
information as to the potential harms (e.g. CD4 count dropping below 250 or detectable viral 
load for >6 months).2 Another solution may be to provide more descriptive terminology to 
accompany the numerical estimates, such as 10% risk of harm as “slight” and 50% risk of harm 
as “extreme”. 
 Another limitation of this study was that we asked participants their willingness to take 
risk in hypothetical studies, which is fundamentally different than enrolling people in an actual 
trial.19 In addition, we used a convenience sample, and our results would likely be more 
generalizable were we to draw from a larger population using a randomization process. 
		 11	
 Future research should include detailed assessment of what a “100” out of 100 “largest 
chance of death” means to respondents. It will also be important to collect comorbidity data, as 
this may help to explain why QOL and EQ-5D statistics were lower than expected. Finally, our 
survey did not collect information on the race of participants, an important point when 
considering perceptions of stigmatization and trust in researchers. 
 
Conclusion 
 Our study found that many HIV-positive people on stable anti-retroviral therapy say they 
are willing to incur substantial risk to be involved in cure research. This enthusiasm appears to 
be motivated by expectations of improved health, reductions in the chance of negative health 
outcomes, and concerns about the safety and efficacy of anti-retroviral medications over multiple 
decades. Other factors such as perceptions of stigmatization, the burden of daily medications, 
and the psychological toll of the infection are important considerations as well. 
 A challenge for health care providers remains the uncertainty surrounding the long-term 
health effects of viral latency, and how to provide accurate prognostic information to patients. 
Similarly, medication effectiveness data is limited to the past two decades, and does not always 
account for factors such as individual adherence.20 Given that the expectation from the many in 
the medical community that HIV-positive people would attain marginal benefit to their health 
and quality of life with a cure,1 it becomes imperative that the motivations for enrollment in such 
dangerous cure trials are understood and any misconceptions are appropriately corrected. 
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APPENDIX A: Systematic Review of the Literature 
 
 
Adult HIV-Positive Patients’ Motivations for Participating in Therapeutic Clinical Trials 
 
Introduction 
 With the advent of highly active antiretroviral therapy (HAART) in the mid-1990s, the 
health outlook for tens of thousands of HIV-positive Americans changed dramatically. No longer 
is HIV a death sentence, but a chronic disease that when managed carefully only minimally 
reduces one’s life expectancy (Deeks, 2013). This improved prognosis has not, however, 
removed the immense burden many people with HIV must endure in their everyday lives. 
Whether it’s regular check-ups to monitor disease progression or the high levels of 
stigmatization that persist, infection with HIV can cause harms well-beyond one’s physical 
health. Certainly there are many HIV-positive individuals who continue to hold out hope for a 
cure. 
 There are those in the research community who share this objective as well, and millions 
of dollars each year go toward finding a permanent solution to one of the world’s deadliest 
diseases (KFF, 2014).  While no safe and scalable means of cure have yet been achieved, there is 
reason to believe that curative trials will be increasing in number in the next decade. One 
example would be the potential to use bone marrow transplantation–the only successful curative 
strategy to date–as it has become much safer in recent years, to the point of being used to correct 
sickle cell disease in adults (Walters, 2015). Such curative trials are likely to present great risks 
to trial subjects, and researchers will be faced with the challenge of recruiting participants in an 
ethically appropriate manner. This challenge will mean having a thorough appreciation for a 
subject’s decision to enroll, and ensuring that the associated risks and benefits of the trial are 
truly comprehended. Even if consented properly, difficult questions will remain: should 
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participants be allowed to risk their lives if their motivations are to escape societal 
stigmatization? Or what if they have a unrealistic expectations of how the disease will progress 
over their lifetime? The answers to these questions are fundamental to ethical research, but they 
are not the focus here. This appendix will review the published literature to establish what is 
currently known about what motivates individuals with HIV to enroll in clinical trials. 
 Dhalla and Poole looked at a related question in 2014 when they reviewed motivators for 
willingness to participate (WTP) in actual HIV vaccine trials. They discovered that the principle 
reasons for enrollment were based on a sense of altruism, while a large percentage of subjects 
also cited personal motivators (e.g. protection from infection) (Dhalla, 2014). The review 
presented here is fundamentally different, however, as the subjects we are concerned with have 
already acquired the virus and therefore have an inherent attachment to trial results. To my 
knowledge this is the first systematic review of its kind to focus on what motivates adult HIV-
positive patients to enroll in therapeutic clinical trials. The purpose is to elucidate consistencies 
between the given motivations by subjects across multiple studies, beginning with the use of 
HAART in 1996. A secondary analysis will include investigating characteristics of individuals 
that are correlated with willingness to participate in clinical trials.  
 
Methods 
 In March 2016, B.M. searched PubMed, Medline, and the Cochrane Library for articles 
that reported HIV-positive patients’ motivations to participate in therapeutic clinical trials. The 
search terms used were “HIV”, “motivators” or “participate”, “research” or “trials”, and “adult” 
(see “Full Search Terms” below). Bibliographies of relevant articles were also reviewed for 
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references that may have been missed with the given search strategy. The search was then 
extended to clinicaltrials.gov to look for unpublished studies and results known as grey literature.  
 To be eligible for inclusion, study 
participants had to be HIV-positive adults (18+) 
directly questioned on their reasons for enrolling in 
either hypothetical or actual therapeutic clinical 
trials for HIV [Table 1]. Both quantitative and 
qualitative approaches were included, consisting of 
both defined lists of responses and open-ended 
questions. Studies earlier than 1996 were not considered, given the change in the meaning of an 
HIV diagnosis at that time, and only English language studies were considered.  
 Studies were abstract screened by two reviewers (BM and MH) to exclude those clearly 
outside the purpose of this review. Articles that passed the initial screen were then appraised in 
their entirety, with particular attention given to whether the reported results addressed 
motivations for participation. Several studies had respondents answer questions on motivations 
for participation among a longer list of questions, the results of those were included as well. 
 Studies deemed appropriate for inclusion were reviewed in detail using a standardized 
rubric for extracting the relevant components into a table (see Results). Data recorded included 
study population, primary purpose of study, methodology, means of measuring WTP, real vs. 
hypothetical trial, primary results, major theme(s), and risk of bias. To be included under primary 
results, the study had to have found a statistically significant (p<0.05) association between an 
answer and WTP (for quantitative studies) or have been one of the most frequent answers given 
(for qualitative studies). When available, the percentage of subjects that stated a particular reason 
Table 1: Inclusion Criteria 
Adults (18+) 
HIV positive 
Therapeutic trial (real or hypothetical) 
Measured motivations for participation 
English Language 
Any study design 
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for enrolling in a study was included in parenthesis. If a clear theme emerged from an individual 
study it was included in the table as well.  
 The risk of bias present in each study was assessed using a 10 question approach 
described by Korhonen et. al, an example of which can be found at the end of this section under 
“Qualitative Appraisal Scale” (Korhonen, 2012). Studies were rated as “good”, “fair”, or “poor”, 
and only those with at least a “fair” scoring were included in the synthesis of results. To receive 
a “good” rating, the study had to fulfil each of the 10 criteria, while a “fair” rating was between 7 
and 9. Anything less than 7 was deemed to be of “poor” quality. 
 Results were summarized by compiling similar responses into standardized wording (e.g. 
“to further biomedical research”). The proportion of studies having found a particular motivation 
were then compared to assess the frequency of that response across the sample. While this can 
help to identify the most consistently given motivations in the literature, there is a risk of bias as 
not all studies asked the same questions in the same manner. As such, results will be presented 
both in aggregate and on their own to avoid obscuring any important findings. The secondary 
analysis of subject characteristics and WTP was collected to potentially enhance the primary 
results table, but due to stated inclusion criteria does not represent all the available literature on 
the topic. 
 
Results 
 Figure 1 shows the progression of the literature search and review. Of the 1017 studies 
initially identified using the previously stated search strategy, only 9 ultimately qualified for 
inclusion based upon the pre-specified criteria [Table 1]. Many of the records removed after 
abstract screening were done so because they focused on HIV naïve participants in preventive 
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trials. The search of unpublished (grey) 
literature revealed one study that was 
eligible for inclusion, however the results 
had yet to be released (Menezes, 2016). 
Of those included in the review, there 
was considerable variability in the 
predefined questions asked of participants 
among studies.  
 The risk of bias was determined 
to be “good” or “fair” for each of the 
studies included in the qualitative synthesis using the criteria of Korhonen et. al. Seven studies 
were deemed “good” because they fulfilled all 10 of the criteria. Two received a “fair” mark for 
having at least 8 out of 10. None of the studies have fewer than 8 criteria fulfilled. 
 When viewing the results of the trials in aggregate, one clear theme that emerges is the 
expectation of participants to receive a health benefit from participation. This factor was listed as 
the primary motivation in 70% of the studies reviewed. Although not every study elicited a 
detailed meaning of “benefit,” the few that did considered it to be delayed progression of disease 
or improved access to health care. Another theme that emerged was the altruistic perception that 
one’s involvement in clinical trials could have benefits for biomedical research generally, or 
other HIV-positive patients specifically.  These two themes, personal health benefit and altruism 
tied to furthering the development of therapies, were not mutually exclusive among trial 
participants.  Of note, one study identified personal financial gain as being a leading motivator of 
participation. However, this particular study (DeFreitas et. al, 2010) did not have willingness to 
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participate as its primary research question, and strictly limited the number of responses 
available to subjects. 
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Table 2 Motivations for volunteering in HIV clinical trial 
 DeFreitas, D., et. al, 2010. Dong, Y., et. al, 2014. Ethier, K., et. al, 1999 Garber, M., et. al.  2007 Gwandz, M.V., et. al, 2006 
Population 56% Caucasian, 19% other, 16% 
African American, and 13% 
Hispanic 
Hospitalized Chinese adults 61.5% W, 28.4% AA, 11% 
Latino 
HIV-infected African-
American 
60% male. 55% AA, 34% 
Latino, 11% White/ Other 
 
Sample size 145 175 213 200 286 
Stated purpose Examine role race/ethnicity 
plays in HIV clinical trial 
enrollment 
To investigate the WTP in 
HIV therapeutic vaccine trials 
among Chinese HIV-infected 
patients.  
Identify factors that influenced 
recruitment in AIDS clinical 
trials 
To determine actual 
participation rates and 
willingness to participate 
in future HIV treatment 
trials among HIV-
infected African 
Americans  
To examine gender differences 
in willingness to participate in 
ACTs among urban HIV-
infected individuals  
Primary Question WTP? No Yes Yes No Yes 
Hypothetical / Real Trial Hypothetical Hypothetical Both Hypothetical Hypothetical 
Location California, US Shanghai Public Hospital, 
China 
Primary care clinic, New 
Haven, NC 
Pittsburgh AIDS Center 
for Treatment, PA 
New York City, NY 
Methods Questionnaire Questionnaire Structured interviews Questionnaire Questionnaire 
List or open-ended 
answers 
List: 49-item survey, scored on 
Likert scale of 1 to 5 
List: subjects willing to 
participate were able to select 
one to three out of the seven 
closed answer choices  
Open-ended questions Single question with 8 
possible answers. 
Participants allowed to 
check as many as desired 
or use open response box 
List: different items used to 
assess health status, substance 
use, trust in scientists, barriers to 
participation, and altruism 
Primary motivations for 
participation 
Not well described in results, but 
African Americans showed a 
trend toward being more willing 
to do a trial for money  
 
Delay/reduce ART side 
effects (76.6%), delay disease 
progression (74.9%), prevent 
opportunistic infections 
(57.7%), prevent drug 
resistance (37.1%), economic 
incentives (15.4%), reduce 
potential transmission 
(36.6%), support family 
(5.1%) 
Potential for personal health 
benefits (61.1%), altruism: 
others will benefit (23.9%), 
improved health care (29.2%) 
The reasons for 
willingness to participate 
in future trials were to 
help find a cure for AIDS 
(86%), to help the HIV 
community (65%) and to 
obtain new and effective 
experimental HIV 
medication (47%)  
For females, importance placed 
on altruism, and the importance 
placed on receiving free care as 
part of a trial. For males, 
importance placed on receiving 
free care in the trial.  
 
Predictors of WTP in 
trials (statistically 
significant, p< 0.05) 
Patients were more willing to 
enroll in a trial if they had been 
asked to be part of a trial in the 
past, were not depressed, took 
fewer doses of medication, and 
had been given a sense of 
understanding of trials  
HIV diagnosis >5 years (OR 
7.12), HIV-related infectious 
complications (OR 2.75), 
Sexual transmission (OR 
2.75) 
No differences in willingness to 
participate based on sex, race, 
risk factor, or history of 
injection drug use. Prior 
awareness of clinical trials 
influenced whether patients 
would participate in a trial.  
The only significant 
factor related to 
willingness to participate 
in future research was 
prior research 
participation (OR = 0.6).  
Women in better physical health 
were less willing to enter ACTs, 
although health status did not 
predict willingness among men. 
Women with higher rates of 
substance use were more willing 
to join ACTs  
 
Major Theme(s) Personal financial incentive Personal health benefit Personal health benefit Altruistic (help research) Personal health benefit 
Quality Assessment Fair Good Good Good Good 
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Table 2 Cont. Motivations for volunteering in HIV clinical trial 
 Luzi, A.M., et. al, 2011 Rivera-Goba, M.V., et. al, 2011 Rodrigues, R.J., et al,  2013 Wendler, D. 2008 
Population 75% Male. 97.6% Italian.  22.9% W, 54.3% AA, 8.6% more 
than one race. Patients 
participating in therapeutic HIV 
trials at NIH 
64% Male. Indian. Infectious 
Disease Clinic, St. John’s 
National Academy of Health 
Sciences 
HIV+ individuals from Argentina, Brazil, and 
Thailand participating in the ESPRIT study for at 
least 6 months  
 
Sample size 332 35 173 582 
Stated purpose To illustrate the integrated biomedical 
and psycho-socio-behavioral 
platforms in support of the enrolment 
Phase I anti-HIV/AIDS preventive 
and therapeutic vaccine trials 
Qualitative study to examine 
factors that racial/ethnic minority 
patients consider when making 
decisions regarding research 
participation  
To explore Indian HIV 
patients’ knowledge of 
research, their processes of 
decision making and motives 
for participation  
 
Why do study participants accept the added risks and 
burdens that clinical research places on them?  
Primary Question WTP? No Yes Yes Yes 
Hypothetical / Real Trial Real Real Hypothetical Real 
Location Rome, Italy National Institutes of Health, MD Bangalore, South India.  Clinics in Argentina, Brazil and Thailand 
Methods  Phone interview Focus groups (4) and in-depth 
interviews (12) 
 
Questionnaire Questionnaire 
List or open-ended 
answers 
List: Four questions with 
dichotomous (yes/no) answer format 
Open-ended Open-ended Both: Open-ended question and then list of 12 
possible reasons regarding why patient participants 
continue to participate. 
Primary motivations for 
participation 
WTP to support biomedical research 
(63.3%), to help other people 
(60.5%), stop progression of disease 
(59.9%), help someone you care 
about (26.2%) 
Optimistic about finding a cure 
(personal benefit), and feeling that 
their participation was 
contributing to this success 
(altruistic) 
 
Self-interest was the main 
motivation for over two thirds 
of the participants. Half of all 
participants reported altruism 
as a motive for participation. 
Single most important reason for participation, open-
ended: medical benefit (56%), personal benefit (19%), 
contribution to science (9%), help others (4%). 
Reasons for participation, list: help patients in own 
country (91%), increase CD4 count (89%), other 
meds not working (46%). 
Characteristics of those 
WTP in trials 
(statistically significant, 
p< 0.05) 
N/A N/A Previous Research 
Participation (OR 6.32), 
Employed (OR 2.48) 
N/A 
Major Theme(s) Both altruistic (support research) and 
personal benefit 
Both altruistic (support research) 
and personal benefit 
Personal health benefit  Personal health benefit 
Quality Assessment Fair Good Good Good 
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 In our secondary analysis we looked for characteristics of patients (e.g. demographics) to 
see if there were any statistically significant associations between these variables and willingness 
to participate in clinical research. While results were generally mixed between studies, a 
common theme that emerged was that participants who had previously been involved in clinical 
trials were more likely to enroll in the future. In general, it also appears that participants in better 
health were less likely to enroll in therapeutic trial, but we hesitate to draw any conclusions from 
such a small number of studies reporting this predictor as significant.  
 
Discussion 
 When reviewing the available literature on HIV-positive individuals’ motivations to 
enroll in clinical trials, the theme that emerges most frequently is the belief that study 
participants will personally benefit from involvement. This is certainly rational from the 
perspective of those entering the trial, but as a substantial benefit from trial participation is 
infrequently seen, there may be unrealistic expectations attached to enrollment. It is imperative 
that researchers make clear the likelihood of personal benefit during the consenting process. 
 The second motivation that was recognized is that of altruism – the belief that 
involvement in the study will have benefit to other HIV patients or the advancement of 
biomedical science. Such an outcome is the most likely of a successful research trial, and this 
review suggests that it should be the primary incentive offered during enrollment. It is both an 
ethically appropriate incentive–because there is less risk of misleading participating that they 
will see personal health benefit–and focusing on altruism should not have a detrimental effect on 
enrollment numbers, as it is already a frequent motivation for many HIV-positive individuals’ to 
participate in studies.  
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 There are several limitations to this review. First, several large databases (e.g. 
ScienceDirect) were not searched for content, and prominent figures in the field were not 
consulted on papers that may not be easy to retrieve through traditional search strategies. Second, 
the studies included in this review, though all focused on motivations for enrollment, were quite 
varied in their methodology. There was a great deal of inconsistency between studies as to the 
type of answers participants were able to give, and large themes (e.g. “personal benefit”) were 
too general for a more nuanced assessment.  
 This review adds to the current literature on motivations for patients to enroll in clinical 
trials by focusing on a population (HIV-positive patients) that had not received sufficient 
consideration up to this point. There remains research to be done to elicit more specific reasons 
for enrollment. In particular, many of the trials reviewed here were hypothetical in nature, and 
there may be important differences between those who actually enroll in research and those who 
just state their intentions. Future reviews could focus more heavily on the secondary questions 
asked here, and expand the inclusion criteria to allow for more papers that address patient 
characteristics and WTP.  
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Full Search Terms 
 
Full search details for PUBMED: 
"HIV" AND ("participate"[All Fields] OR "motivators" [All Fields]) AND ("research" [All 
Fields] OR "trials" [All Fields] OR "trial" [All Fields]) AND ("humans"[MeSH Terms] AND 
"adult"[MeSH Terms]) 
 
 
Qualitative Appraisal Scale 
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APPENDIX B: Methods 
 As this paper has laid out, the survey data brought to light a number of notable factors 
related to HIV-positive people’s perceptions of a cure. This was best presented in a descriptive 
manner, and only a short portion of the “Results” section mentions the more rigorous statistical 
analyses that were undertaken. This section explains in detail the steps that were taken to look 
for associations between the dependent and independent variables in our sample. 
 
Independent variables 
 From the survey data, we were able to isolate 14 dependent variables for analysis. This 
included: sex, age, educational attainment, years with HIV, years on HIV medications, general 
health, EQ-5D index score, expectation of medication failure in next 20 years, expectation of 
side effects from medications in next 20 years, amount of perceived stigma, household financial 
situation, employment status, expected change in health in five years with cure, and subjective 
numeracy score. The multivariable analyses that were run ultimately excluded “expectation of 
medication failure in 20 years” due to its high correlation with “expectation of side effects from 
medication in 20 years.” 
 The EuroQol five dimension questionnaire (EQ-5D) is a standardized instrument for 
measuring generic health status. The five questions concern mobility, self-care, performing usual 
activities, pain/discomfort, and anxiety/depression. For each question, one of five responses can 
be given: “no problem,” “slight problem,” “moderate problem,” “severe problem,” and “unable” 
(Shaw, 2005). The scores form each these questions are then combined into a single index score 
ranging from 0 to 1 (Calc, 2005).  
		 30	
 The subjective numeracy scale (SNS) is a self-reported measure of one’s perceived 
aptitude for mathematics, as well as one’s preference for receiving information, numerical or 
otherwise (Fagerlin, 2007). It has been validated as a reasonably good predictor of a person’s 
actual mathematical ability (Zikmund-Fisher, 2007). The scale consists of eight questions, with 
the first four asking about competency with fractions, percentages, calculating a tip, and 
calculating retail discounts. For each, respondents can answer using a 6-point Likert-type scale 
ranging from “Not at all good” to “Extremely good.” Questions 5 through 8 ask how respondents 
prefer to view information: tables or graphs (“Not at all helpful” to “Extremely helpful”), 
percentages or prose (“Always prefer words” to “Always prefer percentages”), and general 
usefulness of numerical information (“Never” to “Very often”).  These responses can then be 
coded and combined into a single score ranging from 0 (lowest) to 6 (highest). 
 Using the 0-100 scale questions on current health and expected health in five years with a 
cure, we were able to develop a new variable known as “expected change in health in five years 
with cure.” This was simply calculated by subtracting expected health in five years with a cure 
from their expected health in five years were they to continue their medications.  
   
Dependent variables 
 The challenges of working with the dependent variables in this data set were explained in 
the “Discussion” section of the paper, but bear repeating here. Our outcome variables assessed 
participant’s willingness to take risk in a clinical trial. This measure came from the question: “If 
asked to take a treatment that included a chance of causing death, what is the largest chance of 
death (0-100) you would accept in order to be cured of HIV?” This proved to be a difficult 
concept for many participants in the study, as illustrated by two points. The first was that a 
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significant number of respondents gave an answer of “50” [Appendix C]. This matters because 
“50” is an answer frequently given when respondents mean “I do not know.” Therefore, we 
cannot view the step from 40 to 45 the same as 45 to 50. This leads to challenges in running 
regressions on the data set without accounting for the “50’s”. The second point concerns the 
respondents that gave an answer of “100”. Much like “50”, without a follow-up question, it is not 
possible to know what exactly this answer means. It could indicate a willingness to take any risk 
for altruistic purposes, that the respondent is suicidal, or that the person answering does not have 
a complete understanding of probabilities.  
 The other outcome measures we used were based on two hypothetical scenarios that 
utilized the traditional 5-point Likert scale. The first asked participants: “If there was a 1 in 100 
chance you would die by taking this HIV treatment, and a 99 in 100 chance you would survive 
and be cured of HIV, would you take this treatment?”. Respondents were given a pictograph 
[Appendix F] that was meant to help them conceptualize one person out of 100. The follow-up 
question flipped the numbers around and asked about much greater risk: “If there was a 99 in 
100 chance you would die by taking this HIV treatment, and a 1 in 100 chance you would 
survive and be cured of HIV, would you take this treatment?” It was expected that these 
questions would be reasonably straightforward, and were asked prior to the “maximum risk of 
death” question to help frame the concept. The result, however, was that a large proportion of 
respondents gave answers that were not internally consistent. This means that their response to 
the “1 in 100” and/or the “99 in 100” contradicted their answer to “maximum risk of death.” This 
presents issues with how best to analyze the data–namely whether to include inconsistent 
respondents or not–and was addressed by running analyses with a variety of approaches (see 
below). 
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Approach to statistical analyses 
 The overall approach to analyzing the survey data was to go searching for correlations 
rather than to test out any particular hypotheses. This was because the survey is meant as the first 
step in a long line of research projects, and these results are intended to inform future research 
rather than confirm theories about HIV-positive people’s motivations. 
 
Part A  
 The initial analyses that were run considered the “1 in 100” chance of death variable as 
the outcome. This variable was made dichotomous, with those that answered “Definitely Yes” or 
“Probably No” considered willing to accept at least some risk, while those that answered 
“Definitely No” or “Probably No” viewed as accepting no risk. This necessarily excludes 
respondents that stated “Don’t Know,” but this was deemed appropriate as they represented only 
a small portion of total participants. Multivariate logistic regression was run with inclusion of 
each of the independent variables listed above. Analyses were conducted with and without basic 
demographic information (e.g. age, education, etc.) to see the effect of their inclusion.  
 
Part B  
 We next turned our attention to the “maximum acceptable risk of death” variable. Given 
the issues outlined previously with this scale, several approaches were taken to balance the 
competing objectives of grouping data in a meaningful manner and avoiding exclusion of a 
significant portion of the data set. It was determined early on that simple linear regression of all 
the data points would not be appropriate due to the presence of “50”s that likely represented “I 
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do not know.” In addition, we were skeptical that a score of “70” was fundamentally different 
from a “90”, as both represented a willingness to take substantial risk. 
 The first method of accounting for all these factors was to place the “maximum risk of 
death” scores into three categories. Respondents that would accept no risk (0), those that would 
accept a minimal amount of risk (>0–10), and those would accept a substantial amount of risk 
(11-99). These categories were established after lengthy deliberation, and neatly divide the data 
into three approximately equal in size groups. Thus divided, it was possible to run multivariate 
ordinal regressions with all of the dependent variables included. A follow-up analysis was run 
using these same categories but removing the “50”s, given the unclear meaning in this response.  
 
Part C  
 Continuing with the “maximum risk” outcome variable, we next separated those that 
would take any risk (>0) from those that would take no risk (0). This allowed us to run 
multivariate logistic regression of the now dichotomous outcome. Next, the “0”s were excluded 
from consideration and the “any risk” group was run as a continuous variable in multivariable 
linear regression. Each of these analyses were run with and without demographics and inclusion 
of “50”s and “100”s was varied. 
 
Part D 
 In an effort to isolate respondents that seemed to understand the “maximum risk” 
question from those that did not, we considered the internal consistency of respondents. This was 
assessed by comparing answers to the “1 in 100” and the “99 in 100” questions to their answers 
to the “maximum risk of death” question. We isolated those that were internally consistent and 
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ran the same sequence of regressions listed above (linear, logistic, and ordinal, as appropriate). 
The inconsistent respondents were then evaluated in a similar manner. 
 
Part E 
 The final set of analyses considered the respondents based upon their subjective 
numeracy score (SNS). Survey participants were divided into tertiles and evaluated separately. 
Once again, the sequence of regressions listed previously (linear, logistic, and ordinal) were run 
to see if any dependent variables would correlate better or worse depending on stated numerical 
ability. 
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APPENDIX C: Results 
Part A 
 When considering the “1 in 100 chance of death” response as a dichotomous outcome 
(“definitely no” or “probably no” vs. “definitely yes” or “probably yes”) we are left with a 
portion of respondents that do not fall into either category. Ten percent of respondents (21 of 
195) said “I don’t know” to the question and were therefore excluded from the analysis.  
 Multivariable logistic regression did not show any significant correlations with the 
independent variables in our model when demographics were excluded. The inclusion of basic 
demographic information (age, educational attainment, employment status) showed two 
variables to be correlated: subjective numeracy score [OR 1.68 (95% CI: 1.146, 2.449), p=0.008] 
and employment status [OR 4.66 (95% CI: 1.658, 13.075), p=0.004].  
  
 
 
 
 
 
 
 
   * multivariable regression results, with demographics 
 
Part B 
 With the “maximum risk of death” variable divided into three categories, it became 
possible to run multivariate ordinal regressions with “0” as 0, “1” as >0 to 10, and “2” as 11 to 
 OR p = 
General Health 0.70 (95% CI: 0.443, 1.112) 0.130 
Side Effects 1.00 (95% CI: 0.986, 1.015) 0.958 
Years with HIV 1.02 (95% CI: 0.939, 1.116) 0.595 
Years on HIV Medications 0.94 (95% CI: 0.850, 1.033) 0.196 
Stigma 1.03 (95% CI: 0.721, 1.455) 0.892 
Finances 1.05 (95% CI: 0.676, 1.637) 0.821 
Subjective Numeracy Scale 1.68 (95% CI: 1.146, 2.449) 0.008 
Change in Health 1.02 (95% CI: 0.991, 1.059) 0.152 
EQ-5D index 0.42 (95% CI: 0.028, 4.543) 0.512 
Age 0.97 (95% CI: 0.926, 1.017) 0.209 
Educational Attainment 1.30 (95% CI: 0.784, 1.763) 0.843 
Employment Status 4.66 (95% CI: 1.658, 13.075) 0.004 
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99. The “100”s were excluded and “50”s included in the first test but not the second. Regardless 
of inclusion of demographics or “50”s, our analyses showed there were no variables that 
correlated with the ordered “maximum risk” outcome.  
 
 
 
 
 
 
 
 * ordinal regression results, with demographics, excluding “50”s and “100”s 
 
Part C 
 Running multivariate logistic regression of those that took any risk (“maximum risk” > 0) 
compared to those that took no risk (“maximum risk” = 0) showed two statistically significant 
odds ratios when the “50”s and “100”s were excluded from analyses: SNS [OR 1.51 (95% CI: 
1.00, 2.29), p=0.050] and Finance [OR 0.546 (95% CI: 0.304, 0.980), p=0.043]. 
 OR p = 
General Health 0.82 (95% CI: 0.526, 1.276) 0.378 
Side Effects 1.01 (95% CI: 0.991, 1.019) 0.457 
Years with HIV 1.01 (95% CI: 0.935, 1.090) 0.805 
Years on HIV Medications 0.99 (95% CI: 0.908, 1.086) 0.882 
Stigma 1.08 (95% CI: 0.774, 1.498) 0.659 
Finances 0.89 (95% CI: 0.587, 1.348) 0.580 
Subjective Numeracy Scale 1.29 (95% CI: 0.919, 1.807) 0.142 
Change in Health 1.02 (95% CI: 0.988, 1.054) 0.216 
EQ-5D index 0.51 (95% CI: 0.034, 7.615) 0.622 
Age 0.99 (95% CI: 0.955, 1.032) 0.727 
Educational Attainment 0.98 (95% CI: 0.648, 1.495) 0.941 
Employment Status 1.26 (95% CI: 0.501, 3.195) 0.619 
 OR p = 
General Health 1.26 (95% CI: 0.722, 2.204) 0.415 
Side Effects 1.00 (95% CI: 0.983, 1.019) 0.900 
Years with HIV 1.02 (95% CI: 0.927, 1.116) 0.722 
Years on HIV Medications 1.04 (95% CI: 0.932, 1.150) 0.512 
Stigma 0.92 (95% CI: 0.603, 1.399) 0.692 
Finances 0.55 (95% CI: 0.304, 0.980) 0.043 
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Treating “any risk” as a continuous variable in multivariable linear regression, and excluding the 
“0”s, “50”s and “100”s gave a single significant correlation: [Finance: 11.79 (95% CI: 4.118, 
19.469), p=0.003].  
 
 
 
 
 
 
 
 
 
Part D 
 This section focused on respondents’ internal consistency between their answers to the “1 
in 100” and “99 in 100” questions and their “maximum risk of death” score. A total of 27 
respondents lacked internal consistency between their “maximum risk” score and “1 in 100” 
answer. Meanwhile, 31 respondents lacked internal consistency between their “max risk” score 
and “99 in 100” answer. Eight survey participants gave answers that were inconsistent on both “1 
in 100” and “99 in 100” compared to their “maximum risk” score. This was achievable by giving 
Subjective Numeracy Scale 1.51 (95% CI: 0.999, 2.291) 0.050 
Change in Health 1.02 (95% CI: 0.982, 1.061) 0.297 
EQ-5D index 0.37 (95% CI: 0.015, 9.369) 0.547 
Age 0.95 (95% CI: 0.899, 1.007) 0.083 
Educational Attainment 1.17 (95% CI: 0.680, 2.029) 0.563 
Employment Status 0.83 (95% CI: 0.253, 2.694) 0.752 
 Coefficient p = 
General Health -5.60 (95% CI: -13.338, 2.142) 0.153 
Side Effects 0.11 (95% CI: -0.131, 0.352) 0.364 
Years with HIV 0.292 (95% CI: -1.168, 1.751) 0.691 
Years on HIV Medications -1.33 (95% CI: -3.058, 0.407) 0.131 
Stigma 0.13 (95% CI: -5.755, 6.006) 0.966 
Finances 11.79 (95% CI: 4.118, 19.469) 0.003 
Subjective Numeracy Scale 0.26 (95% CI: -6.105, 6.620) 0.936 
Change in Health -0.22 (95% CI: -0.751, 0.314) 0.415 
EQ-5D index -6.69 (95% CI: -54.046, 40.669) 0.779 
Age 0.61 (95% CI: -0.067, 1.292) 0.076 
Educational Attainment -1.81 (95% CI: -9.137, 5.524) 0.624 
Employment Status 15.57 (95% CI: -1.193, 32.343) 0.068 
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a “max risk” of “0” and also stating that one would take both the “1 in 100” and “99 in 100” 
scenarios.  Or, alternatively, giving a “max risk” of “100” and stating that one would not take 
either “1 in 100” or “99 in 100” scenarios. In total, 50 respondents were identified as not being 
internally consistent, and for the purposes of these analyses were separated from the other data. 
 The respondents that were not internally consistent were considered first. Similar 
regressions to those in parts A–C were undertaken, with varied inclusion of demographics and 
the “50”s and “100” maximum risk scores. Under no circumstances were any of the independent 
variable found to correlate in a statistically significant manner with our outcome measures. 
 We next ran regressions on the 128 respondents that were deemed to be internally 
consistent. Treating “1 in 100” as a dichotomous outcome and leaving in the “50s” and “100s” 
gave similar findings to this method in Part A. Both SNS [OR 1.78 (95% CI: 1.095, 2.890), 
p=0.020] and employment status [OR 3.83 (95% CI: 1.075, 13.635), p=0.038] were once again 
statistically significant, while the others variables did not meet our p=0.05 threshold. 
 
   
 
  
 
 
 
 
 Making the outcome variable ordered categorical (0, >0 to 10, 11 to 99) as in part B, and 
still focusing exclusively on internally consistent answers, leaves us with only 80 of 179 (46%) 
 OR p = 
General Health 0.71 (95% CI: 0.407, 1.222) 0.214 
Side Effects 1.00 (95% CI: 0.992, 1.035) 0.220 
Years with HIV 1.06 (95% CI: 0.954, 1.181) 0.277 
Years on HIV Medications 0.97 (95% CI: 0.824, 1.067) 0.327 
Stigma 1.14 (95% CI: 0.756, 2.162) 0.524 
Finances 1.27 (95% CI: 0.744, 2.162) 0.381 
Subjective Numeracy Scale 1.78 (95% CI: 1.10, 2.891) 0.020 
Change in Health 1.03 (95% CI: 0.991, 1.081) 0.121 
EQ-5D index 0.53 (95% CI: 0.032, 9.032) 0.664 
Age 0.97 (95% CI: 0.916, 1.018) 0.193 
Educational Attainment 1.07 (95% CI: 0.606, 1.880) 0.822 
Employment Status 3.83 (95% CI: 1.075, 13.635) 0.038 
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of the initial respondents. With the inclusion of all independent variables there were three that 
had statistically significant odds ratios: years on HIV medications [OR 0.860 (95% CI: 0.752, 
0.983), p=0.027], change in health with a cure [OR 1.061 (95% CI: 1.009, 1.116), p=0.020], and 
employment status [OR 3.97 (95% CI: 1.148, 13.730), p=0.029]. 
 
 
 
 
 
 
 
 
 Continuing with this select group of participants, we repeated the process from part C and 
treated “maximum risk” as a dichotomous outcome (0 = no risk, 1 = any risk). Once again, 
removing the “50”s and “100”s leaves us with only 46% of our original sample. As in the 
previous analysis, the same independent variables gave statistically significant odds ratios: years 
on HIV medications [OR 0.682 (95% CI: 0.475, 0.980), p=0.039], change in health with a cure 
[OR 1.11 (95% CI: 1.000, 1.241), p=0.049], and employment status [OR 10.50 (95% CI: 1.169, 
94.437), p=0.036]. 
 OR p = 
General Health 0.57 (95% CI: 0.321, 1.008) 0.053 
Side Effects 1.01 (95% CI: 0.990, 1.026) 0.394 
Years with HIV 1.10 (95% CI: 0.993, 1.229) 0.067 
Years on HIV Medications 0.86 (95% CI: 0.752, 0.983) 0.027 
Stigma 1.09 (95% CI: 0.720, 1.653) 0.681 
Finances 0.98 (95% CI: 0.579, 1.662) 0.944 
Subjective Numeracy Scale 1.29 (95% CI: 0.822, 2.022) 0.268 
Change in Health 1.06 (95% CI: 1.009, 1.116) 0.020 
EQ-5D index 3.56 (95% CI: 0.128, 99.233) 0.455 
Age 1.00 (95% CI: 0.953, 1.045) 0.944 
Educational Attainment 0.98 (95% CI: 0.558, 1.727) 0.950 
Employment Status 3.97 (95% CI: 1.148, 13.730) 0.029 
 OR p = 
General Health 0.66 (95% CI: 0.249, 1.769) 0.413 
Side Effects 1.01 (95% CI: 0.980, 1.038) 0.550 
Years with HIV 1.37 (95% CI: 0.991, 1.894) 0.057 
Years on HIV Medications 0.68 (95% CI: 0.475, 0.980) 0.039 
Stigma 0.98 (95% CI: 0.499, 1.921) 0.951 
Finances 0.44 (95% CI: 0.190, 1.038) 0.061 
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 The final analysis of the internally consistent respondents focused only on those that 
agreed to accept some risk, and treated the “maximum risk” outcome variable as continuous. 
This time the “0”s were excluded, along with the “50”s and “100”s, which left just 66 of 179 
responses (37%) in consideration. Multivariable linear regression was conducted and revealed 
only a single variable to correlate with our outcome measure in a statistically significant manner: 
finances [OR 12.30 (95% CI: 3.381, 21.214), p=0.008]. 
 
 
 
 
 
 
 
 
 
Part E 
 Our final approach to the survey data was to divide it into tertiles by SNS. The lower 
tertile contained 56 respondents, with SNS scores ranging from 1 to 3.375. The middle tertile had 
Subjective Numeracy Scale 1.28 (95% CI: 0.656, 2.488) 0.471 
Change in Health 1.11 (95% CI: 1.001, 1.241) 0.049 
EQ-5D index 2.68 (95% CI: 0.025, 290.963) 0.680 
Age 0.92 (95% CI: 0.832, 1.011) 0.084 
Educational Attainment 2.20 (95% CI: 0.795, 6.105) 0.129 
Employment Status 10.50 (95% CI: 1.169, 94.437) 0.036 
 Coefficient p = 
General Health -5.02 (95% CI: -13.609, 3.572) 0.247 
Side Effects 0.047 (95% CI: -0.232, 0.327) 0.735 
Years with HIV 0.40 (95% CI: -1.297, 2.089) 0.641 
Years on HIV Medications -1.03 (95% CI: -3.180, 1.120) 0.341 
Stigma -0.0050 (95% CI: -7.256, 7.246) 0.999 
Finances 12.30 (95% CI: 3.381, 21.214) 0.008 
Subjective Numeracy Scale -1.37 (95% CI: -8.701, 5.952) 0.708 
Change in Health -0.014 (95% CI: -0.707, 0.680) 0.969 
EQ-5D index -3.20 (95% CI: -58.127, 51.729) 0.907 
Age 0.68 (95% CI: -0.059, 1.418) 0.071 
Educational Attainment -1.70 (95% CI: -10.860, 7.464) 0.712 
Employment Status 7.36 (95% CI: -12.096, 26.813) 0.451 
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58 respondents (scores ranging from 3.5 to 4.625). The upper tertile had 58 respondents (scores 
ranging from 4.75 to 6).  
 Simple linear regression focusing on the highest tertile did not reveal any independent 
variables that correlated with the “maximum risk” outcome measure. This did not change 
whether or not the “50”s and “100”s were included or not. Similarly, simple linear regression of 
the lowest tertile did not find any statistically significant correlations.  
 Consideration of only the middle SNS, however, found several independent variables to 
be correlation with our outcome: general health [-14.88 (95% CI: -26.69, -3.067), p=0.015], 
expectation of medication side effects in next 20 years [0.445 (95% CI: 0.0846, 0.806), 
p=0.017], years since HIV diagnosis [2.872 (95% CI: 0.679, 5.065), p=0.012], years on HIV 
medications [-4.434 (95% CI: -6.829, -2.039), p=0.001], expected change in health with a cure 
[1.32 (95% CI: 0.262, 2.380), p=0.016], and employment status [25.43 (95% CI: 5.77, 45.08), 
p=0.013]. 
 
 
 
 
 
 
 
 
 
 
 
 
 Coefficient p = 
General Health -14.88 (95% CI: -26.690, -3.067) 0.015 
Side Effects 0.45 (95% CI: 0.0846, 0.806) 0.017 
Years with HIV 2.87 (95% CI: 0.679, 5.065) 0.012 
Years on HIV Medications -4.43 (95% CI: -6.829, -2.038) 0.001 
Stigma -5.13 (95% CI: -2.483, 12.753) 0.179 
Finances 7.092 (95% CI: -4.551, 18.734) 0.223 
Subjective Numeracy Scale -2.65 (95% CI: -5.201, 4.941) 0.868 
Change in Health 1.32 (95% CI: 0.263, 2.380) 0.016 
EQ-5D index 23.77 (95% CI: -40.567, 88.099) 0.457 
Age 0.46 (95% CI: -0.478, 1.398) 0.325 
Educational Attainment 0.78 (95% CI: -8.810, 10.365) 0.870 
Employment Status 25.43 (95% CI: 5.766, 45.085) 0.013 
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APPENDIX D: Expanded Discussion 
 The statistical analyses conducted on our risk taking outcome measures did not provide 
evidence of any clear associations. There had been speculation when crafting the survey that 
factors such as perceived level of stigmatization or educational attainment would correlate with a 
willingness to take risk. However, as described in Appendix C, it takes a great deal of 
manipulation of the data to find any statistically significant correlations.  
 One method of stratifying the analyses that was expected to make a difference was 
dividing respondents into tertiles by their subjective numeracy scores (SNS). The thought was 
that those with higher SNS would be better at working with numbers and probabilities, and 
would therefore be more likely to have correlating independent variables. On the other side, we 
expected those with lower SNS to be less likely to have variables that correlated with their risk 
scores due to a self-described dislike of numerical information. Neither of these predictions were 
borne out, as no statistically significant correlations appeared for either the high or low 
groupings. To our surprise, the middle SNS group had several variables that correlated in a 
significant manner, for which we do not have a good explanation.   
 Ultimately, we believe these lack of associations is the result of a flawed outcome 
measure in the “maximum risk of death” score. The measure is not particularly intuitive and it is 
uncommon for people to think about risk taking in this manner. While a 0-100 scale is preferable 
from the perspective of researchers analyzing the data, there may be superior methods of asking 
individuals to assess their own propensity to take risk. One alternative would be to use a 5-point 
scale, with categories that include: “no risk”, “little risk”, “moderate risk”, “extreme risk”, or “I 
don’t know”.  It would be important to include an “I don’t know” option to avoid the confusion 
that arose with interpreting the “50”s on the 0-100 scale. Another alternative would be to make 
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the scenarios more specific, for example: “Would you be willing to have a detectable HIV RNA 
for > 6 months and for your CD4 count to fall to < 250 during treatment interruption in pursuit of 
a cure?” This should help paint a clearer picture in the minds of participants as to the potential 
downsides of entering a cure trial. It could also be presented in such a way that only a 
dichotomous (yes/no) answer would be allowable, making analysis more straightforward. 
 It is possible that there are such a variety of reasons why someone would enroll in a 
clinical trial that confounding will prevent isolating singular variables, regardless of the outcome 
measure used. As an example, there were several well-off respondents that faced little 
stigmatization who stated they would accept substantial risk for altruistic reasons. Meanwhile, 
there were several low-income, highly stigmatized adults that also stated a high willingness to 
take risk, but were motivated by the the idea that cure would improve their personal 
relationships. Taken together, it would be challenging to pull from this data a single factor that 
correlated with the high risk scores for both groups of respondents. 
 Assessing a complex issue, such as risk taking, using purely quantitative methodology is 
challenging. The free response section of this survey adds a great deal to our understanding of 
the thought processes of HIV-positive individuals, but is limited by an inability to follow-up with 
respondents about unclear answers. From this understanding arose the idea of conducting one-
on-one interviews with HIV-positive people with similar backgrounds to those involved with the 
survey [Appendix E]. These qualitative interviews followed a similar structure as the survey, but 
allowed for probing of unclear or inconsistent answers and helped to clarify participant’s 
motivations for enrolling in cure trials. 
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APPENDIX E: Qualitative Interviews 
 
 The survey provided substantial insight into the lives of people with HIV and was an 
important first step in evaluating potential motivations for entering into risky clinical trials. 
However, the nature of such a standardized survey is that many questions are raised that cannot 
be answered due to the method of data collection. In our case, for example, questions arose as to 
the meaning of taking a 100% chance of death in a trial. This could be interpreted a number of 
ways, from a general belief that any risk is appropriate in pursuit of a cure, to a desire to sacrifice 
one’s body for humanity, to a misinterpretation of the scale. Without the ability to follow-up 
immediately after this type of answer is given, the true meaning of “100” is unknown.  
 In addition, there were many topics that came up in the free response section that were 
not directly measured in the remainder of the survey. From the two questions, “What would an 
HIV cure mean to you?” and “How would your life be different (and what would be the same) 
now and in the future if you were cured of HIV?”, several broad themes could be recognized. 
These themes, as outlined in the body of the paper, include the effect of HIV on romantic 
relationships, the burden of medications, the psychological burden of the illness, and feelings of 
altruism, among others.  
 To address the inherent short-comings of the standardized survey, it was determined that 
the best way to proceed would be to conduct a series of one-on-one qualitative interviews with 
people with HIV. This allowed for deeper probing of answers that were inconsistent or unclear. 
The participants were presented with open-ended questions modeled after the survey and with 
the same pictographs as the survey to assist in understanding the risk scenarios [Appendix F]. 
Unlike the surveys, the topic of remission was included, as many ongoing HIV studies are now 
listing this as the outcome rather than cure (clinicaltrials.gov).  
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 Recruitment was done primarily through a contact of one of the lead investigators, and 
proceeded in a snow-ball fashion. This managed to provide a diverse sample of individuals from 
around the Triangle region of North Carolina. In total, 10 people sat down for audio recorded 
interviews lasting between 45 and 75 minutes. These interviews were immediately transcribed 
and the recordings were destroyed to protect the privacy of those involved. The backgrounds of 
the participants are presented here to provide context to their individual responses: 
 
Interview 1: White male, 60s, wealthy, advanced degree, 20 years since diagnosis 
 
Interview 2: African American woman, 60s, near poverty line, high school degree, recovering 
addict, 10 years since diagnosis 
 
Interview 3: African American woman, 50s, below poverty line, some high school, recovering 
addict, 10 years since diagnosis 
 
Interview 4: White male, 50s, near poverty line, advanced degree, 15 years since diagnosis 
 
Interview 5: White man, 40s, middle class, advanced degree, 20 years since diagnosis 
 
Interview 6: African American male, 40s, below poverty line, high school degree, recovering 
addict, 7 years since diagnosis 
 
Interview 7: White male, 60s, near poverty line, involved in previous trials, 25 years since 
diagnosis 
 
Interview 8: African American male, 30s, below poverty line, 2 years since diagnosis 
 
Interview 9: African American male, 50s, near poverty line, 10 years since diagnosis 
 
Interview 10: African American female, below poverty line, 6 months since diagnosis 
 
 These interviews did not answer every question that arose during our analysis of the 
survey data, but they did help shed light on a number of inconsistent or unclear responses. The 
following section presents the most illuminating answers in the hope of painting a more detailed 
picture into the everyday lives and aspirations of people with HIV. 
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Stigma 
 The topic of stigma arose unprompted in each of the interviews, and for participants that 
were open with their status, each had a powerful personal anecdote to share: 
Interview 1 
“I remember going to state conferences and all of these fag jokes and all of this shit and people 
with HIV deserve or with AIDS deserve what they got and hearing that and just feeling like 
alright sure I deserve it.”  
 
Interview 2:  
“When I was first diagnosed I remember going to the doctor and the man coming in the room 
with his white coat on and then leaving back out and then coming back in with gloves, glasses, 
the hair thing and I was like OMG.”   
 
“We went to a dental office and they discriminated against us. they disclosed our information in 
the lobby which other people were waiting to see the dentist.”   
 
“I guess a cure for me would be…to see you on the street and you ask me how I am doing, and I 
can stay in the crowd full of people, you know I am feeling bad today it is related to my HIV and 
nobody flinch or back away.” 
 
Interview 3: 
“And I was so hurt that day cause I went for the hives and that doctor, I stayed there three hours 
before I got in the back and when I got in the back the doctor looked at my chart.  He said you 
have HIV, I can’t help you.  You have to go back in the front.  And I end up waiting three more 
hours before I was seen.” 
 
“I’m not allowed to see any of my grandkids because of my HIV status.  Their mother thinks that 
if they talk to me or be around me they’ll get it.” 
 
Interview 6: 
“I don’t like the stigmatism a lot of people put on HIV… it’s still a lot of stigmatism with HIV.  
But it’s better than what it used to be.” 
 
Interview 7: 
“I am not openly with it to strange people…The rejection I guess is the biggest thing.  It is 
nonacceptable because a lot of people do not realize there are so many people are there they still 
as far back as HIV has been around they are just as strongly against it now as it was the day it 
came out.” 
 
Interview 8: 
“I had to separate myself from certain black people because they’ll say the HIV is just a tool to 
kill black people or something like that. And you can get rid of it by going off your meds and 
doing this therapy, and doing this natural therapy.” 
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Interview 10: 
“Then they found out, she went and bought plastic plates, plastic spoons, plastic forks, 
everything.  Then she also has a little can of spray stuff in the bathroom that says, kills virus, 
they’re supposed to clean it.” 
 
 
Health Effects of HIV / Treatment 
 Most of those interviewed discussed the current health problems they were dealing with. 
While their complaints were varied in scope, a consistent theme was that they attributed these 
problems primarily to the medications rather than having harbored the virus in a dormant state 
for years or decades. This is generally the perspective of the medical community as well, but 
recent research is raising concerns about the effects of the virus itself over the long-term (Deeks, 
2013). It is evident from the participant answers below that significant uncertainty remains, and 
several were curious whether a cure would reverse the changes they attributed to being HIV-
positive. 
Interview 1: 
 “I have many complications, and I have neurological issues that they believe are tied to HIV…I 
have cognitive issues that I have been tested for and I am not nearly where people of my age 
average…” 
 
Interview 2: 
“For me personally the fatigue was my #1 side effect and I think that is another reason I stayed 
on crack so long.” 
 
Interview 5: 
 “I’ve got a metabolic issue that has kicked in. I’m resistant to insulin… my muscles have been 
incredibly tensed up and they got into a cycle of chronic freeze… those are the main things I’ve 
dealt with.  From a life-threatening perspective, there’s heart disease, there’s stage III kidney 
disease. Oh, and hypercholesterol… some of it is probably age and some of it is HIV and some of 
it is medication.” 
 
Interview 6: 
 “Coming off some of those medications.  I believe I could have more energy to put into what I’m 
doing.  I could, my focus would be better.” 
 
Interview 7: 
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“The doctors say that is why I do not have a leg today because the medications were so toxic 
back in those days that we do not know where it was from clinical trials or where it was actually 
some of the medications I took was so toxic they actually destroyed a lot of my arteries.” 
 
Interview 8: 
“I have a lot of complications…HIV brought out HPV in, in me and warts and I have to deal 
with them” 
 
“I’m too young for most of these problems but for some reason I have back problems now, 
inflammation days.” 
 
Effect of HIV on personal / romantic relationships 
 One of the most consistent survey free response answers regarding the benefit of a cure 
was the ability to reconnect with family, date openly and engage in sexual intercourse more 
freely. This topic is closely tied to notions of stigma as well as concerns of transmission 
(reasonable or otherwise), and it came up repeatedly in the one-on-one interviews: 
Interview 2:  
“When my mom would visit me she would not sit on my furniture. So it was a strain there and I 
used to purposely because my parents live in Virginia so I would purposefully hold a 
conversation out of meanness so you can sit down.” 
 
Interview 3: 
“I have seven brothers. I told them in ’99. At first all of them cut me off. They did not deal with 
me. They did not talk to me. Damn sure better not get near me. Would not sit behind me. Would 
not go to the bathroom behind me. Nothing.” 
 
“There isn’t intimacy really…you got to be so cautious because even though both of you are HIV 
positive if you have unprotected sex you start another strand.” 
 
Interview 4: 
“[Being HIV-positive] did have an impact on what we did in bed which in turn had an impact on 
I really do believe that is why the relationship did not last past seven years.” 
 
Interview 5:  
“It’s also affecting my social life and you know, I have no social life at this point because I just 
don’t.  I’m not comfortable sharing my status with people.” 
 
“It’s been more difficult for me to find partners than it has been for people who are not revealing 
their status publically or are not positive… I end up not having a lot of second dates.” 
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“I think [a cure] would relieve a lot of pressure on a lot of people, both negative and positive, to 
not think so much about the HIV.” 
 
Interview 7: 
“I have got brothers and sisters that have no idea, that have no idea… I have to live a lie in 
order for them to still love me and care for me the way I feel like they do I have to live a life.  I 
am not the person they think I am.” 
 
“I have never got into a full relationship again after I was HIV” 
 
“I do not have to tell that, I feel like it’s not my responsibility to have to tell you every time we go 
to have sex I am HIV positive.” 
 
Interview 8: 
“I think on perception from my family would probably not change a whole bunch [with a cure] 
because of the fact that everybody, like especially in this part of the world, in the Bible belt, view 
it as like a sexual sin or something…Of course they would be happy, you know, but I think it 
would be just like, okay you took care of this problem, now let’s move down to the gay problem.  
You know, let’s move down to the social status problem, now let’s move down to the way he 
wears his hair, now let’s move down to the way he talks and stuff like that, you know?  And now 
let’s move down to his religion, you know?”  
 
Interview 9: 
“I told my mother and I think it was somewhere around the area of two to three weeks after I 
told her we were together somewhere and I was getting ready to leave and I kissed her on the 
cheek and she literally recoiled, recoiled and wiped her cheek.” 
 
“Once I was diagnosed I refused to have an intimate relationship with someone because to this 
day I still have not dealt with disclosure…for fear of rejection and being stigmatized.” 
 
 
Willingness to accept risk for a cure 
 Using the pictographs from the survey [Appendix F], each of the participants was 
presented with three scenarios. The first asked “If there was a 1 in 100 chance you would die by 
taking this HIV treatment, and a 99 in 100 chance you would survive and be cured of HIV, 
would you take this treatment?”. The second flipped the numbers, and made it a 99 in 100 
chance of death versus a 1 in 100 chance of survival. The third was left blank and asked 
participants to state the highest risk of death they would be willing to take in a cure study. The 
resulting answers, much like the survey data, covered all levels of risk aversion. 
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“1 in 100”: 
Interview 1: “Definitely.” 
Interview 2: “I will say yeah but I am going to ask you 99 questions so you are like do not give it 
to her just let her go but I would say yes” 
Interview 3: “Pretty good odds. I will do it.” 
Interview 4: “Hell yes.” 
Interview 5: “At this point, no… right now I’m stable and I don’t need a new med…if that fails I 
don’t know what options I would have.” 
Interview 6: “Yeah… You have to look at it, that one percent hopefully wouldn’t be me.” 
Interview 7: “I sure would even if I had to be the one to go.”   
Interview 8: “Quite possibly. Because there’s like thousands and thousands of people that died 
in trials just so I could be alive and have this medicine. So, I mean I think, for me 
to say no, would probably be rather small and selfish of me.” 
Interview 9: “You’re going to think I’m a nut. I would volunteer to be the one to die if 99 could 
be cured.” 
Interview 10: “I couldn’t do it because, no.  Because that, out of that ninety-nine, I could be that 
one to die, so I’m not going to do that.” 
 
“99 in 100”: 
Interview 1: “That is not a trial that should be offered.” 
Interview 2: “Right now I would say yes but actually going to do it that day I would probably 
would back out… I did everything that I wanted to do in life.  I have my 
grandchildren.  So if I die today I am at peace.” 
Interview 3: “This study would never get approved.  It would not get passed the IRB first of all 
but no I would not, obviously not take part in a study like that.” 
Interview 4: “Yes. I would really, for real.  I would take that chance because look at the 
possibilities, that I could be the one that, hell, I can make it… I’d take my chance.  
You gamble every day with HIV anyway.” 
Interview 5: “Don’t think so… I’m looking at that one percent that made it and all the rest of it 
don’t make it.” 
Interview 7: “No… I would be willing to give up too easily and I do not think the friends and the 
people who are HIV would be willing for me to do that either so.” 
Interview 8: “I’d be fucking scared. And most likely I probably wouldn’t…like now, in my young 
life, I probably wouldn’t. Because I still life, my life ahead of me, you know. If I 
was older, I probably would.” 
Interview 9: “I’d still do it honestly, because I told you, I’m not afraid to be the one that died 
because my, the way I look at that is the one that did get cured, they’re going to 
know how he got cured.” 
 
“Maximum Risk”: 
Interview 1: “I would do it with 25%.  I would do it with seriously consider with 40%.” 
Interview 2: “I am going to say no more than 20%.”  
Interview 3: “I would say the odds in favor of success would need to be at least 70-75% positive 
versus 25-30% negative.”   
Interview 4: “Regardless of what the percentage was, I’d try it. I would try it.”   
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Interview 6: “I would probably say fifty, half and half…with how well I’m already doing, having 
HIV and all, I think that I would have a greater chance than some receiving the 
cure than not receiving it.  Based on me going to my doctor, based on what they’re 
telling me about my labs and all of that, and based on my strength and my 
beliefs… I was thinking about it, I said, well there’s a fifty percent chance that I 
could make it, or there’s a fifty percent chance that I might not make it decided just 
to split it up.” 
Interview 7: “I have had a pretty good life and I would love for them other people I have seen so 
many young people that has died with this that I have become friends with and 
loved through organizations like this that I think I could do it at 50%.” 
Interview 8: “The max I would do would be fifty-fifty, split it.”   
Interview 9: “Me personally, just for the sake of research and helping a population. I don’t have 
a limit.” 
Interview 10: “When it comes a day that they tell me, and I see a lot of people that already took 
this medicine, I mean a lot of them, and they’re still alive then I may do it. Other 
than that…” 
 
 
Remission vs. cure 
 An important concept in therapeutic HIV research is that of remission because many of 
the current techniques for cure involve stimulating latent HIV-infected CD4 T-cells for 
identification and destruction. Such strategies are liable to leave certain T-cells harboring HIV in 
their latent state, and therefore the virus could reemerge many years down the line. This is 
fundamentally different than a “cure” due to the uncertainty associated with the treatment 
outcome. As we explained to study participants, “remission means that the virus would not be 
completely eliminated, but it would not be detectable on our tests. Your CD4 count would be 
normal, and you would no longer need to take anti-retroviral medication medications. However, 
it would also be necessary for you to come into the office a few times a year to be sure that the 
virus had not returned.” The interviews showed a variety of responses to this topic, with some 
seeing it as an insignificant change from their present situation, and others viewing it as 
comparable to a cure. This perception affected their willingness to take risk in a clinical trial for 
remission rather than cure. Here are several thoughts on a remission trial: 
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Interview 1: “Yeah, I would be open to that.” 
Interview 2: “I would still be married to it.” 
Interview 3: “That’s what it sounds like I got now with the Stribild [medication].” 
Interview 4: “I mean again my age the difference between remission and eradication is you 
know I mean I may get cancer anyway or I may have a heart attack anyway so it is 
not that important to me.” 
Interview 6: “Remission from HIV is like remission from anything else that you might be going 
through, you know, that would be wonderful to me.” 
Interview 7: “I look at remission probably different than you simply because I have been in 
remission with MS for many, many years…I have had MS for longer than I have 
had HIV… And it seems like when I go into remission I do real wonderful.” 
Interview 8: “I’d rather just take my meds than being in remission, because remission sounds the 
same as undetectable. Only with a trap door…Like I could be way more 
susceptible to giving it to somebody…But if remission was a step to cure I would 
definitely be down for it.” 
Interview 9: “Actually the word remission to me makes it sound a little scary.	Because when you 
think remission, you think cancer. I do. And so for that term to be used its kind of 
suspect if you will.” 
Interview 10: “The remission, I wouldn’t dare. Because I wouldn’t stop taking my medicine, I 
wouldn’t do it. I’m not going to risk it.” 
 
 
Motivations 
 This next section addresses the potential motivations participants may have for enrolling 
in a clinical trial by trying to identify the expected changes a cure would have on different areas 
of life. The thinking is that this may help to identify reasons why people on stable anti-retroviral 
therapy for many years would be interested in a clinical trial. The topics covered include those in 
the written survey as well as themes brought up in the free response section. 
 
Medication burden 
 In this study, most participants had been on anti-retroviral medications for years, if not 
decades. Taking one or more pills every day had become a routine part of life. However, while 
some had adapted to this daily repetition others continued to view it as a burden. As the highest 
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cited life style change in the free response of the survey, we were eager to draw out the meaning 
of these medications in the interviews: 
 
Interview 1: 
“I mean I am on 12, I am on 12 different medications.  I am only on 2 for HIV.”   
 
Interview 2: 
“I do not like really the direction that HIV is going in now because I feel like it is giving people 
false hope by saying we can take a pill once a day and you know you are going to be okay but 
they are not talking about the side effects of the medication having to be committed, just like 
being in a marriage, to that pill every day if you do not take it.” 
 
Interview 3: 
“I’m at the point where I have to take a lot of different pills for a lot of different things because 
the HIV meds is causing one problem so I have to take this pill to cover that problems, and that 
pill to cover it. I mean, it’s too much.” 
 
Interview 4: 
“[A cure] would mean not having to take those four or five pills every morning.” 
 
Interview 5:  
“This is my pill dispenser and I’ve been on a mission to reduce my pill count. Every time I go in I 
say, well let’s try to reduce my pill count; I end up coming away with two new prescriptions.  
That’s what it takes to survive.” 
 
Interview 7: 
“I have been HIV so long that actually it would be nice to get up in the morning and not have to 
worry about taking your medicine.” 
 
Interview 8: 
“The times that I’m away from home and the stigma of when I was around other people for any 
amount of time or had to live with someone else for a small amount of time, hiding medicine, 
keeping it out of sight and stuff like that.” 
 
Interview 10: 
“Finding a cure would really change a whole lot because therefore you won’t have to take no 
medicine on a daily basis.” 
 
 
Improvement in health  
 From the survey it was evident that most people with HIV attributed much of their 
current health state to the virus. Many believed that a cure would not only prevent decline over 
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the near future but actually lead to an improvement in health. This was consistent with half of the 
interviewees, while the other half viewed a cure as not significantly improving their health status. 
Interview 3:  
“I ain’t worried about [my health]. I don’t care. I don’t care. Cause I know long as I take them 
little funny little pills, multicolor pills, I be alright.” 
 
Interview 4:  
 “[A cure] would hopefully mean that I would not have to worry so much about my bone health 
…you know some HIV drugs cause bone loss and I have had my right shoulder replaced 
surgically last year about this time.  I have had cervical fusion surgery because of arthritis in my 
neck.” 
 
“In very small ways [a cure] would have an impact on me but I am 60 years old so it is not going 
to make me more inclined to go back looking for a full time career, and I do not think it would 
necessarily increase my lifespan at this point.” 
 
Interview 5: 
“If I were to be cured and still have stage III kidney disease and still have hyperlipidemia and all 
the other side effects which may or may not go away when I stop my meds. that wouldn’t be so 
cool.  But if all that stuff were to go away, I would be thrilled with it.” 
 
Interview 6: 
“I believe I would live significantly longer with a cure. If I was to receive a cure then a lot of 
things like I was stating, in, in my lifestyle, I would change for me.  I mean, I would be probably 
excited so I would probably go out there and run, think about running a marathon or something.  
I have no problem with walking, and I don’t have a problem with doing things, but I have to kind 
of get started to continue it.” 
 
Interview 9: 
“[With a cure] I’d expect to live longer.  Just to know that’s something that a normal person 
with an uncompromised or rather me with a compromised immune system couldn’t fight off 
whereas if I was normal or uncompromised then I would be able to fight it off.” 
 
Finances 
 In the survey, one of the few consistent correlations with our outcome measure 
“maximum risk of death in pursuit of a cure” was the participant reported financial situation. 
Those with greater financial hardship generally took greater risks. With the interviews, financial 
considerations arose in two manners. The first was that the majority of participants lived below 
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the poverty line and struggled to make ends meet. Many had seen their disability checks remain 
stable over decades while others costs increased substantially. The second was on the matter of 
monetary incentives for trial participation, which was not given as a primary motivating factor 
by anyone interviewed here.  
Interview 3: 
“Right now I’m on a fixed income; I get 750 a month.  This apartment is 450, my lights is almost 
100, my water is almost 60.  I have to have my phone so I can get to and from the doctor, to call 
my Medicaid riders, and to call doctors.  Uh, I just don’t.  At the end of the day I’ll have $14.00 
left after I pay all my bills and that’s not including my cleaning supplies, my personal items, 
none of that.  We, we, if, what I’m looking for is an initiative to help us out during the month or 
something, or help us get a raise in what the hell we getting cause 750, come on.  Can you live 
on 750?” 
 
Interview 4: 
“I enrolled in trials because I felt like it was a way that I could make a contribution…and they 
pay you a little you know money which is always helpful when you are disability.” 
 
“I am in a situation where it is very difficult to live on disability/social security alone and I am 
not having any much success in finding in other sources of income even though I pick up the 
occasional dog sitting job or what have you so my quality of life is not what it used to be or what 
I would like it to be.” 
 
Interview 5: 
 “If I did not have excellent benefits it would be even more of an incentive [to participate in 
trials].  I know people that pay $40.00 for a refill. For medication and I’ve got so many 
medications, that would bankrupt me at this point.”   
 
“If these things, these expenses come up like this, I’m either going to have to get a roommate or 
move into a smaller house or, you know there are going to have to be adjustments to my lifestyle 
and I’m lucky that I can squeeze down and go to the next level and keep going.” 
 
“I’ve tended to shy away from accepting any kind of reimbursement for any research that I do. 
Just because other people can use the money and to get somebody else into the trial with the 
same amount of money that you’re giving me.” 
 
Interview 6: 
“I mean I like going to the research.  It’s not all about the money, you know the money to give an 
incentive to go, but to me it’s all about going to these researchers and then giving the doctor a 
chance to be able to you know, try to find a cure for it.” 
 
Interview 9: 
“Socially, economically. Yes, it’s held me back in so many ways.”   
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Psychological burden  
 For participants who did not experience significant side effects from their daily 
medications, a common theme was that infection was more of a psychological burden than a 
physical one. Several people that mentioned this mental toll also spoke of having a small social 
circle and the effort they went through to keep their status hidden. 
Interview 1: 
“In many ways I think [a cure] would be a relief that I would not have to worry that somehow it 
would break out of the reservoirs.” 
 
Interview 2: 
“So am I going to die of AIDS, no.  It is always going to be on label now.  I hate it but I cannot 
change it so I live with it… Having HIV/AIDS is not for me has not been a physical disease as 
much as it has played with me mentally.” 
 
Interview 3:   
“Every day I have two things on my mind at all times.  My [addiction] recovery and my HIV.” 
 
“HIV is an addiction really because you got to feed it at all times. If you not feeding it 
medication, you got to feed it food because if you don’t you’re going to get sick.” 
 
Interview 7: 
“Because something you constantly think about, it does not ever leave you and I do not know 
whether that is good or bad but it is something that HIV sort of lives your life really…no matter 
what you do you cannot forget it because you have got to take that medication by the handful 
morning and night and actually you deal with HIV constantly.” 
 
Interview 8:  
“It’s a mental, psychological freedom, it’s itself; it’s also itself made caged.  But the cage 
protects you from the outside world as well.  So it’s kind of, it’s bittersweet you know, it’s 
defensive but it’s trapping, enclosing.” 
 
Interview 9: 
“I think the hardest thing for me about being positive now is the small percentage of your brain 
that occupies knowing that you have HIV. It used to be a large percentage. As the years have 
gone by, it shrunk to where it was like one side of my head, like half my brain was always 
preoccupied with that thought. And as the years went by, it became less and less but nevertheless 
it’s kind of like you can never totally go ahhh, to relax.” 
 
“I don’t cook as much. I am scared to cut stuff up certain ways, like really, really small because 
I don’t want to slice my finger. You know? It’s the smallest things.” 
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Interview 10: 
“The bad thing about when you HIV, every time you go outside you have the feeling that 
someone’s always looking at you, always talking about you and stuff.” 
 
“To be really honest, I don’t really think that by the time they do come out with a cure, 
everybody going to know that I was once upon a time with HIV.  And a lot of ignorant 
people…they still going to look at me same type of way.” 
 
 
Altruism 
 A common motivation for participants in medical research is to advance science for the 
purposes of helping others. The reality is that little research, in any field, provides a direct 
therapeutic benefit to study participants. In these interviews, those with background knowledge 
of the current state of HIV research directly addressed this point, while those less familiar did so 
in a more abstract manner. Regardless, nearly every participant touched on a desire to be 
involved in research for the benefit of others.  
Interview 1: 
“I would consider it at 50/50 you know because I believe in the only way we are going to come 
up with a cure is through research and I know that I know the research I know the protocol 
development process well enough to know that something like that 1/100 is never going to 
happen…If not for myself, for other folks with the virus.” 
 
Interview 2: 
“I want everybody to live but realistically in order to find a cure somebody is going to live and 
somebody is going to die.” 
 
Interview 3: 
 “I would take the risk so I could help others because that’s something I like to do, help other 
people.  You know? Give them the knowledge that wasn’t given to me.”   
 
Interview 4: 
“I feel like I know that they are not going to find a cure in my lifetime or it is very doubtful that 
they will but I feel like even at this stage I by participating in the clinical trials have helped 
people that are catching the virus now or people that might catch it in the future have a better 
outcome health wise overall.” 
 
“It would be nice in the sense that if they if a cure were developed while I am still around to see 
it happen feeling of accomplishment, success that I helped contribute to, in some small way at 
least, I contributed towards that cure that will save millions of people’s lives.” 
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Interview 6: 
“I mean I like going to the research.  It’s not all about the money to give an incentive to go, but 
to me it’s all about going to these researchers and then giving the doctor a chance to be able to 
try to find a cure for it.” 
 
Interview 7: 
“I made so many loving friends through HIV that I totally give up my life that other people 
would not have to go through this shit.” 
 
 
Would not change life 
 Most of the participants interviewed had been dealing with HIV for several years, and for 
many the idea a cure was not something they expected to see anytime soon or even in their 
lifetimes. They generally had internalized their status as a part of their identity. Several people 
related that they had become so accustomed to having HIV, or had already had it for so long, that 
they did not think a cure would change their day to day life substantially. 
Interview 1:  
“I do not think my daily life would change.  I am very happy.  I am very active… I am planning 
my life whether or not there is a cure.” 
 
Interview 2: 
“What do I think a cure would look like?  I see me as being cured because I am still here.” 
 
Interview 7: 
“I really do not know what life would be like without it it has been so long.” 
 
Interview 10: 
“It’s not going to change anything.  Still stigma going to be there, and still people going to find 
something to say.” 
 
 
Summary 
 The interviews described here add a great deal to our understanding of HIV-positive 
peoples’ motivations for enrolling in clinical trials. Much like the survey data, there is a clear 
willingness to take risk in cure trials, but also a wide variety of motivations for doing so. The 
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benefit of these interviews over the survey was that participants were not limited in their 
responses to a predetermined scale, and could take the conversation whatever direction they 
chose.  
 As was seen in the surveys, feelings of stigmatization were commonly discussed in the 
interviews. However, the interviews highlighted the fact that stigma can mean many different 
things to different people. For some it was a persistent feeling that everyone in public places was 
constantly judging them, while others described an intense fear of being rejected by romantic 
interests.  Notably, multiple people said that they do not experience stigma because they actively 
keep their HIV status a secret. This contributed to an intense psychological burden of constantly 
worrying that they would be outed and would lose the affection of friends and relatives as a 
result. This raises questions about the ~20% of survey respondents that said they were not 
stigmatized, and if some of them felt this way because they chose to live a very private life.  
 The interviews also brought to light many more issues that the survey glossed over or did 
not address directly. This includes altruistic motivations of respondents, particularly among those 
that had been on HAART for many years and felt a strong sense of reverence for those that had 
been in the early drug trials that developed the current therapies. Additionally, the notion of 
“remission” is vital to distinguish from “cure”, as some of the most promising research will lead 
to uncertainty about whether the virus has been completely eliminated. Among those 
interviewed, there were those that saw cure and remission as equally positive, and others that 
saw remission as being a worse outcome than their current medication regimen due to the 
associated uncertainty.  
 Taken together, the survey data and qualitative interviews make a meaningful 
contribution to the present literature on HIV-positive individuals motivations for enrolling in 
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risky clinical trials. The next steps will include improving the survey questions, reaching a 
broader population, and potentially conducting focus groups. Once patient motivations have been 
clearly documented, it will be important to gather similar information from physicians to see 
where the medical community and HIV-positive individuals have similar perspectives, and more 
importantly, where their perspectives diverge. 
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APPENDIX F: Qualitative Interview Framework 
 
Life with HIV 
1) How does having HIV affect your life? 
2) How healthy do you feel? 
Follow-up 1. How have your medications affected your health? 
What side effects have you experienced from your medications? 
Follow-up 2. How would staying on your current therapy affect your health in the next 10-20 
years? 
 
Cured of HIV 
You may or may not know this, but unfortunately, a cure for HIV does not yet exist. However, medical 
experts are working hard to develop new treatments in the hopes of completely removing HIV from the 
body. If successful, patients who are cured will no longer need to take HIV medications.  
 
1) What would being cured of HIV mean to you? 
Follow-up 1.  In what ways would your life change were you to be cured of HIV? 
Follow-up 2.  How would your immediate health change if you were cured? Long term? 
2) A cure would not prevent you from becoming infected again. If you were cured, how concerned would 
you be about becoming reinfected?  
Social Stigma 
1) Have people treated you differently since you were diagnosed? 
Follow-up 1. Do you think that would change if you were cured? 
Follow-up 2. Do you have an example of when you were stigmatized that you would like to share? 
2) How did your loved ones respond when you told them you were HIV positive? 
 
Intimate Relationships 
1) How has your diagnosis affected your intimate relationships? 
Follow-up 1.  How would things change were you to be cured? 
 
Thank you for sharing these personal details about your life with HIV. 
I’d like to now move to asking some questions about HIV research. 
 
Clinical Trials 
1) In general, how do you feel about clinical research? 
Follow-up 1.  Have you enrolled in any trials? (Y/N) Can you tell me about that  experience? 
2) What would motivate you to enter a research study ? 
Follow-up 1.  What would you need to hear from your doctor to enroll? 
 
Risk attitudes 
Suppose a successful treatment of HIV has been developed, but the new treatment is risky. Some people 
who receive the treatment will die because of a fatal side effect; the rest will be cured of HIV. Please take 
a look at these figures:   
 
1) If there was a 1 in 100 chance you would die by taking this HIV treatment, and a 99 in 100 chance you 
would survive and be cured of HIV, would you take this treatment? 
2) If there was a 99 in 100 chance you would die by taking this HIV treatment, and a 1 in 100 chance you 
would survive and be cured of HIV, would you take this treatment? 
3) If asked to take a treatment that included a chance of causing death, what is the largest chance of 
death you would accept in order to be cured of HIV? 
Follow-up 1. Can you tell me about your decision? 
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Follow-up 2. Why did you not want to take greater risk? 
Follow-up 3. Why not less risk? 
 
In Remission 
A different possible treatment outcome is something called “remission,” which means that the virus 
would not be completely eliminated, but it would not be detectable on our tests. Your CD4 count would be 
normal, and you would no longer need to take anti-retroviral medication medications. However, it would 
also be necessary for you to come into the office a few times a year to be sure that the virus had not 
returned. 
Follow-up 1. How would being in remission compare to being completely cured? 
Follow-up 2. How concerned would you be of transmitting the virus to someone else, even if you 
were several years out from a positive test? 
 
Conclusion 
1) What would you want physicians who are researching an HIV cure to know? 
2) Do you have any questions? 
 
 
 
Pictographs 
 
If there was a 1 in 100 chance you would die by taking this HIV treatment, and a 99 in 100 chance you 
would survive and be cured of HIV, would you take this treatment?  
 
 
 
 
If there was a 99 in 100 chance you would die by taking this HIV treatment, and a 1 in 100 chance you 
would survive and be cured of HIV, would you take this treatment? 
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If asked to take a treatment that included a chance of causing death, what is the largest chance of death 
you would accept in order to be cured of HIV? 
 
 
 
In other words, how many people (out of the 100 people shown on this display) would have to die from 
the treatment before you would no longer be willing to accept the treatment? ____ out of 100 (Please 
write a number from 0 to100) 
